Icosavax, Inc. (ICVX)
Feb 20, 2024 - ICVX was delisted (reason: acquired by AstraZeneca)
15.31
0.00 (0.00%)
Inactive · Last trade price on Feb 16, 2024
Icosavax Revenue
In the year 2022, Icosavax had annual revenue of $582.00K, down -92.54%.
Revenue (ttm)
$582.00K
Revenue Growth
-92.54%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
60
Market Cap
766.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 582.00K | -7.22M | -92.54% |
| Dec 31, 2021 | 7.80M | 6.19M | 382.80% |
| Dec 31, 2020 | 1.62M | - | - |
| Dec 31, 2019 | 0 | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionICVX News
- 1 year ago - ICOSAVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX - PRNewsWire
- 1 year ago - ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX - Business Wire
- 1 year ago - SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of Icosavax; Is the Deal in the Best Interest of Shareholders? - Business Wire
- 1 year ago - Why AstraZeneca Is Buying Icosavax For $1.1 Billion - Investopedia
- 1 year ago - AstraZeneca will pay up to $1.1B to acquire Icosavax, a Univ. of Washington biotech spinout - GeekWire
- 1 year ago - This Vaccine Stock Soars 46% After $1.1 Billion AstraZeneca Deal - Barrons
- 1 year ago - AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data - Business Wire
- 1 year ago - AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion - Forbes